TheraRadar
← Back
Data updated: Jun 28, 2026

INTERPHARM

Generics

INTERPHARM is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Neurology.

1987
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

INTERPHARM's Key Drugs

INTERPHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

INTERPHARM's Recent FDA Approvals

New NDA/BLA approvals for INTERPHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

INTERPHARM's Therapeutic Areas

INTERPHARM's approved drugs and pipeline span 3 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 33%
1 drugs
Cardiovascular 33%
1 drugs
Neurology 33%
1 drugs

INTERPHARM's Top Competitors

INTERPHARM's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

INTERPHARM Pipeline Snapshot

Active clinical trials for INTERPHARM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling